Teva Pharma (TEVA) Lowers Quarterly Dividend 75% to $0.085; 1.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Credit Suisse Downgrades Teva Pharma (TEVA) to Neutral
August 4, 2017 6:01 AM EDTCredit Suisse downgraded Teva Pharma (NYSE: TEVA) from Outperform to Neutral with a price target of $25.00 (from $39.00).
Analyst Vamil Divan said as they look ahead they believe there are still no signs of stabilization for some of the key issues impacting TEVAs core... More
Teva Pharma (TEVA) Cracks Fresh Low, Now Down 19.65%
August 3, 2017 11:17 AM EDTTeva Pharma (NYSE: TEVA) Cracks Fresh Low, Now Down 19.65%
... MoreTeva Pharma (TEVA) Sinks 16% on Weak Results, Outlook
August 3, 2017 8:18 AM EDTTeva Pharma (NYSE: TEVA) shares sink nearly 16% in pre-open trade following weak results and outlook.
... MoreTeva Pharma (TEVA) Misses Q2 EPS by 4c, Lowers FY EPS Guidance, Cuts Dividend
August 3, 2017 6:33 AM EDT(Updated - August 3, 2017 6:40 AM EDT)
Teva Pharma (NYSE: TEVA) reported Q2 EPS of $1.02, $0.04 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $5.7 billion versus the consensus estimate of $5.76 billion.
GUIDANCE:
Teva Pharma sees Q3 2017 EPS of $4.30-$4.50, versus the consensus of $4.74.
We... More